Tumor marker detection reagents are crucial tools in modern medicine for assisting in early cancer screening, diagnosis, treatment response monitoring, and prognosis assessment.
These reagents detect specific biomolecules, such as proteins, carbohydrate antigens, hormones, or gene mutations, in blood, body fluid, or tissue samples, providing clinicians with crucial diagnostic evidence.
There are many types of tumor markers, including common ones like alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), and carbohydrate antigens such as CA125 and CA19-9. These markers often show abnormal expression in patients with certain tumors. For example, AFP is commonly used to screen for liver cancer, while PSA is closely associated with prostate cancer. Detection reagents use highly sensitive immunoassay techniques (such as chemiluminescence and enzyme-linked immunosorbent assays) to accurately quantify the concentrations of these markers, helping physicians determine the presence, progression, or risk of recurrence of a tumor.
With the advancement of precision medicine, the sensitivity and specificity of tumor marker detection reagents are continuously improving. Newer-generation reagents not only detect single markers but also enhance diagnostic accuracy through combined analysis of multiple markers. Furthermore, the rise of liquid biopsy technology has made blood-based tumor DNA (ctDNA) detection possible, further promoting its application in noninvasive, dynamic monitoring of tumor progression.
However, tumor markers are not absolutely specific; their levels may be affected by inflammation, infection, or other non-neoplastic conditions. Therefore, comprehensive assessment requires the integration of imaging, pathology, and other diagnostic methods. In the future, with the integration of artificial intelligence and big data technologies, tumor marker detection reagents will become even more intelligent, enabling earlier and more precise tumor management and providing personalized treatment strategies for patients.